logo-loader
viewShield Therapeutics PLC

Shield looking to exploit 'significant' market opportunity after US approval for Feraccru

Shield Therapeutics PLC's (LON:STX) Carl Sterritt sat down with Proactive London's Andrew Scott following US regulatory sign-off for their iron deficiency treatment.

The Food & Drug Administration has given broad label approval to Feraccru, which will be marketed as Accrufer in America.

It is already on sale in Europe.

Quick facts: Shield Therapeutics PLC

Price: 164.5 GBX

LSE:STX
Market: LSE
Market Cap: £192.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Shield Therapeutics ties up US$63mln deal for Feraccru in China

Shield Therapeutics (LON:STX) has signed an exclusive agreement worth up to US$63mln for its iron deficiency treatment Feraccru to be sold in China. Chief Executive Carl Sterritt came to talk to us at Proactive London and he couldn't hide his enthusiasm at the deal making it over the line,...

2 weeks, 2 days ago

2 min read